MapLight Therapeutics, Inc. MPLT
MapLight Therapeutics, Inc. (Nasdaq: MPLT) is a CNS/neurology/psychiatry drug developer. Its lead program, ML-007C-MA, is in Phase 2 for Schizophrenia. Its next catalyst on record is ML-007C-MA: VISTA Phase 2 topline (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ML-007C-MA — VISTA Phase 2 topline (H2 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ML-007C-MA | schizophrenia (ZEPHYR) | small molecule | Phase 2 |
| ML-007C-MA | Alzheimer's disease psychosis (VISTA) | small molecule | Phase 2 |
Recent results and decisions
- Jul 27, 2026met ZEPHYR Phase 2 met primary endpoint: 210/3 mg BID cut PANSS total by 4.5 points vs placebo at Week 5 (ES 0.37, p=0.015); 330/6 mg QD numerically better but not significant.
The trial met its primary endpoint, with the 210/3 mg twice-daily (BID) dose demonstrating a statistically significant and clinically meaningful reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo at Week 5.
Filing - Jun 22, 2026missed IRIS Phase 2 missed its primary endpoint (ABI-Social Communication at Week 12); prespecified adolescent subgroup with ABC-I >16 (N=20) showed ES 1.33, nominal p=0.013 on irritability.
The study did not meet its primary endpoint of change from baseline to Week 12 in the caregiver-reported Autism Behavioral Inventory (ABI)–Social Communication Domain score.
Filing - May 14, 2026completed enrollment ZEPHYR Phase 2 completed enrollment of 307 participants; topline expected by mid-August 2026.
Completed enrollment of 307 participants in the Phase 2 ZEPHYR trial for schizophrenia, with topline results expected by mid-August of 2026.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.